- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ATL names new division SonoSight
ATL Ultrasound has announced that the distribution date for its handheld division took place on April 6 (SCAN 3/18/98). The new company, called SonoSight, will trade on the NASDAQ National Market under the ticker symbol SONO. ATL Ultrasound
ATL Ultrasound has announced that the distribution date for its handheld division took place on April 6 (SCAN 3/18/98). The new company, called SonoSight, will trade on the NASDAQ National Market under the ticker symbol SONO. ATL Ultrasound shareholders of record on March 30 will receive one share of SonoSight for every three shares held of ATL.
SonoSight has filed a 510(k) premarket notification for its first product, with commercial launch anticipated in 1999, according to ATL. A prototype of the first handheld system, targeted for use in women's healthcare, is expected within a few months. Other models are being developed for internal and emergency medical use.
In other SonoSight developments, Kevin Goodwin has been tapped as president and CEO of the company, with Kirby Cramer serving as chairman. Cramer is a member of the ATL board of directors and president of investment firm Keystone Capital Company.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
